Stealth BioTherapeutics Granted Orphan Drug Designation of Elamipretide for Treatment of Patients with Primary Mitochondrial Myopathy

By | October 2nd, 2017|Categories: Uncategorized|

BOSTON, October 2, 2017 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development (OOPD) has [...]